Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.
about
Updating the OMERACT filter: implications for imaging and soluble biomarkersIs blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) andCost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulinBiomarkers of immunotoxicity for environmental and public health researchPrognosis Research Strategy (PROGRESS) 2: prognostic factor researchCost-effectiveness of insulin analogues for diabetes mellitus.Biomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma.Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological studyA Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials.Biomarkers and surrogate endpoints in glaucoma clinical trials.Optimal therapy recommendations for the prescribing and use of blood glucose test strips.Application of biomarkers in the development of drugs intended for the treatment of osteoarthritisPitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicineThe need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysisTracking biocultural pathways in population health: the value of biomarkersMolecular pathology.Role of Serum cartilage oligomeric matrix protein (COMP) in the diagnosis of rheumatoid arthritis (RA): A case-control study.Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial
P2860
Q27014889-9DFA39FD-E2AE-41E9-8171-CAD0F2E310ADQ27025943-7EBA26F8-31FC-4B10-9309-AD53D801D8E2Q28268410-43720929-E405-4277-B6A6-DF11719B6782Q28389042-24BF254A-746C-44D8-B7F5-7F7A165601E1Q28709212-3146FD1A-F22B-4DC5-82F7-2935BE25A74FQ30485897-01A59CC2-D726-42A0-A483-7D4D8AC81696Q33756518-5DF391F6-639A-42E4-9DFA-4D8376C255BBQ34567058-D6A96304-7380-4343-AF1A-E0113D729402Q35016789-DB3B9C3C-2320-47BE-AAAB-5C8BA4A43E96Q35681400-646242E7-4D8E-4C80-B65A-4956ECEC20D3Q35912696-3A0193EB-F2B9-4F19-BC40-828C531636AEQ36137747-EF71621D-6483-44D0-A8C6-98707AD19204Q36598469-4E586DBF-9928-4CCF-AF63-2D2578FA6D3EQ36690546-B2695983-A46E-4A65-83D0-3B679D273805Q36790324-C8DF9100-5B9D-4528-89B8-810F447A1B8EQ37312451-5FD679E1-198A-408D-8CF6-A3BC9F2A9D05Q37385281-814219E9-1E50-4BA9-A645-3AA2D9D1AB78Q38003803-96F4DB5B-9B22-477F-A6CB-D4F8A83A81D7Q42340175-825D61C9-0545-452A-803B-D7A79B8D2E75Q56395625-1B695024-09C9-4C39-BAE5-848607D317A0
P2860
Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Definitions and validation cri ...... cal levels of evidence schema.
@en
Definitions and validation cri ...... cal levels of evidence schema.
@en-gb
type
label
Definitions and validation cri ...... cal levels of evidence schema.
@en
Definitions and validation cri ...... cal levels of evidence schema.
@en-gb
prefLabel
Definitions and validation cri ...... cal levels of evidence schema.
@en
Definitions and validation cri ...... cal levels of evidence schema.
@en-gb
P2093
P1476
Definitions and validation cri ...... ical levels of evidence schema
@en
P2093
Barry Bresnihan
Clifton O Bingham
Doug Altman
George Wells
Kent R Johnson
Maarten Boers
Marc Buyse
Marissa N Lassere
Michael Hughes
P304
P407
P577
2007-03-01T00:00:00Z